Literature DB >> 19906157

Purification and characterization of a new recombinant factor VIII (N8).

L Thim1, B Vandahl, J Karlsson, N K Klausen, J Pedersen, T N Krogh, M Kjalke, J M Petersen, L B Johnsen, G Bolt, P L Nørby, T D Steenstrup.   

Abstract

SUMMARY: A new recombinant factor VIII (FVIII), N8, has been produced in Chinese hamster ovary (CHO) cells. The molecule consists of a heavy chain of 88 kDa including a 21 amino acid residue truncated B-domain and a light chain of 79 kDa. The two chains are held together by non-covalent interactions. The four-step purification includes capture, affinity purification using a monoclonal recombinant antibody, anion exchange chromatography and gel filtration. The specific clotting activity of N8 was 8800-9800 IU mg(-1). Sequence and mass spectrometry analysis revealed two variants of the light chain, corresponding to two alternative N-terminal sequences also known from plasma FVIII. Two variants of the heavy chain are present in the purified product, namely with and without the B-domain linker attached. This linker is removed upon thrombin activation of N8 rendering an activated FVIII (FVIIIa) molecule similar to plasma FVIIIa. All six known tyrosine sulphations of FVIII were confirmed in N8. Two N-linked glycosylations are present in the A3 and C1 domain of the light chain and two in the A1 domain of the heavy chain. The majority of the N-linked glycans are sialylated bi-antennary structures. An O-glycosylation site is present in the B-domain linker region. This site was glycosylated with a doubly sialylated GalNAc-Gal structure in approximately 65% of the product. In conclusion, the present data show that N8 is a pure and well-characterized FVIII product with biochemical properties that equal other FVIII products.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906157     DOI: 10.1111/j.1365-2516.2009.02135.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  34 in total

1.  Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

Authors:  Maartje van den Biggelaar; Jesper J Madsen; Johan H Faber; Marleen G Zuurveld; Carmen van der Zwaan; Ole H Olsen; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2015-04-21       Impact factor: 5.157

2.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

3.  Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.

Authors:  H Agersø; H R Stennicke; H Pelzer; E N Olsen; E P Merricks; N A Defriess; T C Nichols; M Ezban
Journal:  Haemophilia       Date:  2012-07-20       Impact factor: 4.287

Review 4.  Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.

Authors:  David J Harvey
Journal:  Mass Spectrom Rev       Date:  2014-05-26       Impact factor: 10.946

5.  Factor VIII C1 domain spikes 2092-2093 and 2158-2159 comprise regions that modulate cofactor function and cellular uptake.

Authors:  Esther Bloem; Maartje van den Biggelaar; Aleksandra Wroblewska; Jan Voorberg; Johan H Faber; Marianne Kjalke; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-09-05       Impact factor: 5.157

6.  Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.

Authors:  D M Karpf; M Kjalke; L Thim; H Agersø; E P Merricks; N Defriess; T C Nichols; M Ezban
Journal:  Haemophilia       Date:  2011-06-20       Impact factor: 4.287

7.  Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.

Authors:  Ulrik H Mistarz; Susheel K Singh; Tam T T N Nguyen; Will Roeffen; Fen Yang; Casper Lissau; Søren M Madsen; Astrid Vrang; Régis W Tiendrebeogo; Ikhlaq H Kana; Robert W Sauerwein; Michael Theisen; Kasper D Rand
Journal:  Pharm Res       Date:  2017-06-23       Impact factor: 4.200

8.  Helical organization of blood coagulation factor VIII on lipid nanotubes.

Authors:  Jaimy Miller; Daniela Dalm; Alexey Y Koyfman; Kirill Grushin; Svetla Stoilova-McPhie
Journal:  J Vis Exp       Date:  2014-06-03       Impact factor: 1.355

9.  A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.

Authors:  Henning R Stennicke; Marianne Kjalke; Ditte M Karpf; Kristoffer W Balling; Peter B Johansen; Torben Elm; Kristine Øvlisen; Flemming Möller; Heidi L Holmberg; Charlotte N Gudme; Egon Persson; Ida Hilden; Hermann Pelzer; Henrik Rahbek-Nielsen; Christina Jespersgaard; Are Bogsnes; Anette A Pedersen; Anne K Kristensen; Bernd Peschke; Wendy Kappers; Frederik Rode; Lars Thim; Mikael Tranholm; Mirella Ezban; Eva H N Olsen; Søren E Bjørn
Journal:  Blood       Date:  2013-01-18       Impact factor: 22.113

10.  Comprehensive N- and O-glycosylation mapping of human coagulation factor V.

Authors:  Cheng Ma; Ding Liu; Dong Li; Junping Zhang; Xiao-Qian Xu; He Zhu; Xiu-Feng Wan; Carol H Miao; Barbara A Konkle; Philip Onigman; Weidong Xiao; Lei Li
Journal:  J Thromb Haemost       Date:  2020-06-14       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.